UCB SA

18 articles about UCB SA

• CEVEC and UCB Sign Agreement for the use of CEVEC's ELEVECTA(R) AAV Manufacturing Technology in Gene Therapy

  9/7/2021

  CEVEC Pharmaceuticals GmbH announced the signing of an agreement with UCB S.A. on the evaluation and use of CEVEC's proprietary ELEVECTA Technology for the research, development, and manufacturing of Adeno-Associated Virus vectors for gene therapy applications.

• UCB SA And Dermira Announce U.S. And EU Regulatory Submissions For CIMZIA (Certolizumab Pegol) For The Treatment Of Moderate-To-Severe Chronic Plaque Psoriasis

  7/25/2017

• Safety Issues Force the FDA to Turn Down Amgen, UCB SA's Osteoporosis Drug

  7/18/2017

• Cipla, Lupin Make Bid for UCB SA’s $1 Billion Generics Unit

  6/1/2015

• UCB SA, Neuropore to Develop Parkinson's Treatment in $480 Million Deal

  1/16/2015

• Dermira And UCB SA Announce Start Of Phase 3 Program For CIMZIA® (Certolizumab Pegol) In Psoriasis

  1/8/2015

• UCB SA Terminates $1.53 Billion Sale Of Generic Drug Unit To Buyout Firms

  12/17/2014

• Illinois-Based Akorn, Inc. Eyes $2 Billion UCB SA Unit In Potential Tax Inversion Deal

  9/12/2014

• UCB SA to Enhance Informatics Environment With Dotmatics' Vortex

  8/7/2013

• Immunomedics, Inc. and UCB SA Announce Restructuring of Epratuzumab License Agreement for Up to $60 Million

  12/28/2011

• UCB SA Release; Long-term Use of Antiepileptic Drug Vimpat(R) (Lacosamide) C-V Reduced Seizure Frequency and Severity and Improved Health-related Quality of Life Measures

  12/5/2011

• UCB SA Pleads Guilty to Illegal Off-Label Marketing of Epilepsy Drug Keppra; to Pay $34.4 Million

  6/9/2011

• UCB SA Plans EUR250M ($334M) Plant To Meet Cimzia Demand

  1/3/2011

• Actient Pharmaceuticals LLC Inks Deal with UCB SA for Marketed Drugs with Global Sales of $53M

  7/30/2010

• UCB SA And Immunomedics, Inc. Release: New Data From EMBLEM(TM) Study Show Pipeline Drug Epratuzumab Provided Significant Efficacy for Patients Suffering From Moderate to Severe Systemic Lupus Erythematosus

  6/16/2010

• UCB SA Subsidiary, Schwarz Pharma, To Pay $22M In False Claims Settlement

  4/30/2010

• Interim Report - Promising Early Results for UCB SA's New Products

  10/22/2009

• FDA: Johnson & Johnson (JOBS), Abbott Laboratories (JOBS), Amgen (JOBS), UCB SA, and Wyeth (JOBS) Arthritis Drugs Raise Cancer Risk in Kids

  8/6/2009